## Abstract Although more than 25 million people in sub‐Saharan Africa have human immunodeficiency virus (HIV) infection, little is known regarding their cancer risk. We investigated cancer risk among persons with HIV/AIDS in Uganda using record‐linkage. We linked records of 12,607 HIV‐infected per
The spectrum of malignancies in HIV-infected patients in 2006 in France: The ONCOVIH study
✍ Scribed by Emilie Lanoy; Jean-Philippe Spano; Fabrice Bonnet; Marguerite Guiguet; François Boué; Jacques Cadranel; Guislaine Carcelain; Louis-Jean Couderc; Pierre Frange; Pierre-Marie Girard; Eric Oksenhendler; Isabelle Poizot-Martin; Caroline Semaille; Henri Agut; Christine Katlama; Dominique Costagliola; the ONCOVIH study group
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- French
- Weight
- 347 KB
- Volume
- 129
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Drug resistance is an increasing problem in the treatment of HIV infection. Tenofovir has been shown to inhibit HIV replication even with thymidine‐associated resistance mutations (TAMs) if they are limited to two or less. Double‐dose of tenofovir disoproxil fumarate (TDF) (600 mg QD) w
## Abstract In the course of an unlinked, anonymous survey of anti‐HIV seroprevalence among antenatal patients in the West Midlands, carried out between November 1986 and March 1990, seven out of 202,012 patient samples were anti‐HIV seropositive. Although the numbers of women infected by heterose
## Abstract Angiitis of the central nervous system (CNS) in patients infected with HIV‐1‐is often associated with concomitant infection or lymphoproliferative disease of the CNS. Four HAART naïve patients infected with HIV‐1 with severe stroke are described. Evidence of vasculitis was found by magn
## Abstract The objective of this study was to assess the factors implicated in an increased or decreased risk of pneumonia, with particular attention to the response to highly active antiretroviral therapy (HAART) and the effect of the polysaccharide 23‐valent pneumococcal vaccination in 300 human